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PERSPECTIVE
Does Heart Failure Confer A
Hypercoagulable State? Virchow’s Triad Revisited
Gregory Y. H. Lip, MD, FACC, Christopher R. Gibbs, MRCP
Birmingham, England
It is well-recognized that patients with congestive heart failure are at an increased risk of
stroke and venous thromboembolism. Nevertheless, stroke, thromboembolism and myocar-
dial infarction have generally been regarded to be end points of secondary importance in large
heart failure trials, when compared with mortality or hospital readmissions. It may well have
been that the incidence of thrombotic events are underestimated. The problem of thrombus
formation (thrombogenesis) in heart failure may therefore be a much more significant
problem than is currently recognized.
The pathophysiology of thrombogenesis in heart failure could well be explained in the context
of Virchow’s original triad. In addition to “abnormal flow” through low cardiac output, dilated
cardiac chambers and poor contractility, patients with heart failure also demonstrate
abnormalities of hemostasis and platelets (that is “abnormal blood constituents”) and
endothelial dysfunction (“vessel wall abnormalities”). These abnormalities contribute to a
prothrombotic or hypercoagulable state, which increases the risk of thrombosis in heart failure
and impaired left ventricular systolic function.
Some observational data are available on the role of anticoagulants in heart failure, and there
is sound evidence to support the use of antithrombotic therapy in patients with heart failure
and atrial fibrillation. However, there are no large-scale prospective randomized controlled
trials of antithrombotic therapy in patients with heart failure who remain in sinus rhythm,
although important studies are in progress. Although the results of these studies are awaited,
measurement of suitable markers of thrombogenesis might prove to be valuable in identifying
“high risk” patients and in determining the nature, duration and intensity of such treatment.
Further information is also needed on the predictive value of various markers of hyperco-
agulability in patients with heart failure, the association between hemostatic variables and the
severity of heart failure, and the effects of different treatments. (J Am Coll Cardiol 1999;33:
1424–6) © 1999 by the American College of Cardiology
Congestive heart failure has long been recognized to pre-
dispose to stroke and thromboembolism, occurring in up to
30% of patients, and is often the cause of death (1,2). Recent
observational data from the studies of left ventricular dys-
function (SOLVD) and V-HeFT studies (3,4) suggest that
mild to moderate heart failure is associated with an annual
stroke risk of approximately 1.5% (being particularly high in
severe heart failure, 4%), compared with a risk of less than
0.5% in those without heart failure. Although the V-HeFT
studies (4) only showed a weak relationship between throm-
boembolic risk and left ventricular ejection fraction, the
Survival and Ventricular Enlargement Study (SAVE) (5)
recently reported an inverse relationship between stroke risk
and ejection fraction, with an 18% increase in stroke risk for
every 5% reduction in left ventricular ejection fraction, thus
clearly relating thromboembolism to severe cardiac impair-
ment and the severity of heart failure. The stroke risk was
also progressive, continuing for the 42-month follow-up
period (5).
In large heart failure trials, stroke, thromboembolism and
myocardial infarction have generally been regarded to be
end points of secondary importance when compared with
mortality or hospital readmissions. It may well have been
that the incidence of these vascular events, which have a
thrombotic basis, was underestimated (6). Indeed, it is
possible that the major cause of sudden death in chronic
stable heart failure is not related to arrhythmia, but (throm-
botic) vascular occlusion (7). The problem of thrombus
formation (thrombogenesis) in heart failure may therefore
be a much more significant problem than is currently
recognized.
Virchow, as long as 150 years ago, recognized three
prerequisites for thrombogenesis: 1) abnormal blood flow;
2) abnormalities in the vessel wall; and 3) abnormalities in
blood constituents. The pathophysiology of thrombogenesis
in heart failure could well be explained in the context of
Virchow’s original triad. Low cardiac output, aberrant flow
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through dilated cardiac chambers and poor contractility may
all produce “flow abnormalities” that predispose to intracar-
diac thrombus formation and subsequent thromboembo-
lism. In left ventricular dysfunction with aneurysm forma-
tion, for example, there is both diastolic and systolic bulging
or asynergy, resulting in severe stasis of blood, with conse-
quent predisposition towards thrombus formation. The
frequency of left ventricular thrombus in patients with
ventricular aneurysms at postmortem can range between
14% to 68%, which is consistent with findings at aneurys-
mectomy (50% to 95%) (1). Despite this, the reported
incidence of systemic thromboembolism in patients with
left ventricular aneurysm actually demonstrates a wide
range, from 0% to 52% (1,8–10). Poor systolic function may
also cause stasis of blood within a dilated left ventricular
cavity (11) and indeed, thrombus is more common in such
patients, particularly when cardiac dysfunction is severe
(12).
Abnormalities of the blood vessel and endothelium rep-
resent another component of Virchow’s triad, and are
indeed relevant, because defective endothelial function has
been demonstrated in heart failure (13). The impaired
release of endothelium-derived nitric oxide (NO) in re-
sponse to stimuli may contribute to the increased peripheral
vasoconstriction that is characteristic of heart failure; the
reduced NO may also promote monocyte and platelet
adhesion to the endothelium, predisposing to in situ throm-
bosis and thromboembolism. An alternative method of
assessing endothelial function relies on the measurement of
specific markers of endothelial damage or dysfunction, such
as von Willebrand factor (vWf), where levels are abnormal
in cardiac impairment (14,15). The final component of
Virchow’s triad, that is, abnormalities in blood constituents
(such as rheology, hemostatic markers and platelet func-
tion), have all been demonstrated in patients with heart
failure (14–17). These abnormalities seem to be due to
systolic or contractile dysfunction, with little contribution
from diastolic dysfunction (15,18).
The proposed mechanisms for these hemostatic abnor-
malities include the flow disturbances that are associated
with heart failure, in view of the correlation between some
hemostatic markers and Doppler indices (18) and neuroen-
docrine activation (14). Furthermore, heart failure is asso-
ciated with high levels of atrial natriuretic peptide and
chronic diuretic use, which may contribute to hemoconcen-
tration, raised hematocrit and corresponding rheological
abnormalities. In the SOLVD and V-HeFT studies, 15% of
patients with mild to moderate heart failure also had atrial
fibrillation, although only 30% to 40% of these patients
received oral anticoagulants (19). Although V-HeFT failed
to identify atrial fibrillation as an independent risk marker
for thromboembolic events (19,20), clearly atrial fibrillation
may account for some of the excess risk of stroke in heart
failure (21). Atrial fibrillation per se is also associated with
abnormalities in hemostasis, which are compatible with a
prothrombotic or hypercoagulable state; these have been
related with blood flow abnormalities (“stasis”) within the
left atrium (22).
Medical treatment for heart failure may reduce mortality
by altering thrombogenesis. Angiotensin converting enzyme
(ACE) inhibitors, for example, have beneficial effects on
platelets, at least in hypertensive patients (23). Although
warfarin has been shown to modify hemostatic markers in
heart failure (15,17), there have been no published prospec-
tive large scale randomized outcome trials to guide clinicians
on the use of antithrombotic therapy, particularly in patients
with severe cardiac impairment. Some have nevertheless
been initiated, such as the Warfarin Aspirin Study in Heart
failure (WASH) pilot study (6). The Veterans Administra-
tion is also conducting the large Warfarin-Antiplatelet Trial
in Chronic Heart Failure (WATCH) in 4,500 patients with
NYHA Class II–IV heart failure and ejection fraction 30%,
who will be randomized to warfarin, aspirin or clopidogrel
(Dr. Barrie Massie, personal communication). The primary
outcomes in WATCH will be all-cause mortality, nonfatal
myocardial infarction and nonfatal stroke in addition to
ischemic events and thromboembolism.
For now, we have to turn to data from observational data,
which are usually retrospective, posthoc analyses. Indeed,
the evidence of benefit from observational studies is actually
conflicting. For example, the SAVE study (5) did demon-
strate an overall 81% reduction in total stroke risk in
patients treated with anticoagulation and a 56% reduction in
those treated with aspirin, and a retrospective analysis of
SOLVD (3) suggested that the use of warfarin and aspirin
were both associated with a better prognosis. By contrast,
the V-HeFT study only reported a low incidence of throm-
boembolism in mild to moderate heart failure, which was
not reduced with warfarin treatment (20).
The presence of the different components of Virchow’s
triad in heart failure leads to an increased risk of thrombo-
genesis; in particular, the presence of abnormalities of
hemostasis, platelets and endothelial function suggest that
heart failure confers a prothrombotic or hypercoagulable
state. The abnormalities in these markers in various disease
populations (such as atrial fibrillation, vascular disease and
heart failure) suggest that a continuum may be present
between “normal,” statistically increased levels of these
markers and overt thrombus formation. If the mechanisms
of thromboembolism are therefore not simply mechanical
but are also related to an underlying hypercoagulable state,
measurement of suitable markers associated with thrombo-
genesis may perhaps be useful in identifying “high risk”
patients and in determining the nature, duration and inten-
sity of antithrombotic therapy. This is pertinent, because
many of these markers of thrombogenesis and endothelial
dysfunction have already been shown to have prognostic
implications, being predictive of mortality and cardiovascu-
lar events. Such risk stratification could perhaps be part of
much-needed large, prospective randomized trials assessing
the efficacy or risks of anticoagulation for patients with heart
failure and sinus rhythm. Further information is needed on
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the predictive value of these markers in patients with heart
failure, the relationship between hemostatic variables and
the severity of cardiac impairment and the effects of different
treatments for heart failure.
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